Merrimack Pharma (MACK) Misses Q4 EPS by 10c

Merrimack Pharma (NASDAQ: MACK) reported Q4 EPS of ($0.41), $0.10 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $21.42 million versus the consensus estimate of $26.58 million.

For earnings history and earnings-related data on Merrimack Pharma (MACK) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Royal Unibrew reports higher interim first-half profit as margins improve
• UBS: 'We Believe Dollar Tree (DLTR) is Turning From a Transformation to a Growth Story'